Tramadol

Speaker 1...and this brings us to tramadol. It’s a weak opioid receptor agonist, but also acts like an SNRI, affecting serotonin and norepinephrine. It’s prescribed for pain relief, but the long-term picture is complex, especially concerning aging and mortality.

Speaker 2Right. We often think about the immediate pain relief, but what does the evidence say about its broader impact? Specifically, we’ve seen associations between chronic opioid use and increased all-cause mortality. For instance, a study in *Public Health* (2024) reported that chronic opioid use was linked to a 37% higher risk of all-cause mortality compared to short-term use.

Speaker 1And it’s not just the opioid component. Combining tramadol with gabapentinoids also raises concerns. *Frontiers in Pharmacology* (2022) found that this combination was associated with a 2.76 times increased risk of CNS depression and mortality. These are serious considerations for long-term treatment.

Speaker 2Absolutely. However, it's crucial to balance this with the fact that unrelieved chronic pain itself is detrimental. For example, *GeroScience* (2025) showed that painful diabetic neuropathy is associated with accelerated epigenetic aging and telomere shortening. So, untreated pain can speed up biological aging.

Speaker 1The key is that while tramadol can offer necessary relief, the evidence about its long-term effects on biological aging and all-cause mortality, particularly concerning falls, sedation, or cognitive issues, is still developing. We don’t fully understand the direct causal links between tramadol and accelerated aging, or even if the observed mortality is purely due to the drug or underlying health conditions requiring its use.

Speaker 2Precisely. It’s about weighing the known benefits against potential long-term risks, and recognizing that there are still many unknowns about the precise mechanisms and long-term implications for biological aging markers like the epigenetic clock.

Speaker 1...and this brings us to tramadol, a pain treatment that acts on opioid receptors, but also has SNRI activity. While it can certainly offer relief, research on its long-term use and broader health outcomes is evolving.

Speaker 2Exactly. For some, it’s a crucial medication. But the question is, what does long-term use mean for biological aging and all-cause mortality? We’re seeing studies that raise concerns.

Speaker 1One study in Public Health 2024 (PMID 38718737) noted that chronic opioid use was associated with a 37% higher risk of all-cause mortality compared to short-term use. This isn’t a direct indictment of tramadol alone, but it certainly puts it within that broader conversation.

Speaker 2And when combined with other medications, like gabapentinoids, the risks can increase further. Front Pharmacology 2022 (PMID 36304170) found that such combination therapy could be associated with nearly a triple odds ratio for CNS depression and mortality.

Speaker 1It's a delicate balance because we know untreated pain isn't benign. GeroScience 2025 (PMID 39847262) highlights that painful conditions, like diabetic neuropathy, are linked to accelerated epigenetic aging and telomere shortening. So, effective pain management is also key to healthy aging.

Speaker 2So, for appropriate, supervised use, tramadol clearly has a role. But the long-term safety profile, especially regarding all-cause mortality and potential for serious harms like falls or dependence, is still being rigorously evaluated. What’s still unclear is the precise dose-response relationship over many years, and how these risks compare to the cumulative harm of specific untreated pain conditions.